Equities

Nxera Pharma Co Ltd

Nxera Pharma Co Ltd

Actions
  • Price (EUR)8.40
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change-17.65%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue12,76615,56917,712
OPERATING EXPENSES
Cost of revenue total3,102926933
Selling, general and admin. expenses, total8,1673,5353,138
Depreciation/amortization1,798842802
Unusual expense(income)(1051)1,0983,031
Other operating expenses, total850(2)
Total operating expense22,17613,85513,833
Operating income(9410)1,7143,879
Other, net(1317)--(311)
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes(10680)1,078433
Provision for income taxes(3487)696(584)
Net income after taxes(7193)3821,017
Minority interest------
Net income before extra. Items(7193)3821,017
Total extraordinary items------
Net income(7193)3821,017
Inc.avail. to common excl. extra. Items(7193)3821,017
Inc.avail. to common incl. extra. Items(7193)3821,017
EPS RECONCILIATION
Basic/primary weighted average shares838281
Basic/primary eps excl. extra items(87)4.6713
Basic/primary eps incl. extra items(87)4.6713
Dilution adjustment------
Diluted weighted average shares838381
Diluted eps excl. extra items(87)4.6313
Diluted eps incl. extra items(87)4.6313
COMMON STOCK DIVIDENDS
DPS - common stock primary issue000
Gross dividend - common stock000
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental787673518
SUPPLEMENTAL INCOME
Depreciation, supplemental983563541
Total special items(1051)1,0983,031
NORMALISED INCOME
Normalized income before taxes(11731)2,1763,464
Effect of special items on income taxes(368)3841,061
Income tax excluding impact of special items(3855)1,080477
Normalized income after tax(7876)1,0962,987
Normalized income avail. to common(7876)1,0962,987
Basic normalized EPS(95)1337
Diluted normalized EPS(95)1337
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.